Navegando por Palavras-chave "Oral findings"

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Avaliação odontológica e danos em dna nas mucopolissacaridoses i, ii e vi
    (Universidade Federal de São Paulo (UNIFESP), 2013-03-27) Guilheiro, Joice Marques [UNIFESP]; D'Almeida, Vânia [UNIFESP]; http://lattes.cnpq.br/7220411418339421; http://lattes.cnpq.br/9906565818359453; Universidade Federal de São Paulo (UNIFESP)
    Background: The goal of the study was to investigate through the comet assay in peripheral blood and analyze in cells of oral mucosa through the micronucleus test damages in DNA leads by GAGs accumulation in patients diagnosed with mucopolysaccharidosis I, II or VI. Moreover, anamnesis and a clinical examination in Dentistry were also performed, and the clinical findings in Dentistry were compared with described by literature. Methods: Twelve patients, treated in Centro de Referência de Erros Inatos do Metabolismo (CREIM - UNIFESP), diagnosed with mucopolysaccharidosis I, II or VI and in enzyme replacement therapy treatment were include in the study. The control group consisted of healthy subjects, with the same age and gender to the patients. For the DNA damage, the comet assay and micronucleus test were performed. An anamnesis and clinical examinations were evaluated for oral manifestations in MPS. The comet assay in peripheral blood was used to detect DNA damages and analyze in cells of oral mucosa through micronucleus to morphological analize and detect cell death parameters. An anamnesis and clinical examinations were evaluated for oral manifestations in MPS. Results: The mean of age of diagnosis for MPS II was 55.75±26.98 months, for MPS VI, 45.5±27.87 months and, for MPS I, 26.75±31.42 months. Significant clinical findings were present in MPS VI (5.25±1.5), followed by MPS I (2.25±1.71), and MPS II (1.5±1.91). The treatment time was 25±23.13 months for MPS I, 36.25±24.5 months for MPS II and, 42±28.56 months for MPS I. The genotoxicity values (comet assay) showed high results in MPS patients, comparing to control group (0.7±1.2). The result for MPS I was 4.7±1.4, in MPS II (higher value), 5.3±1.3 and, 3.2±1.4 for MPS VI. Micronucleus test mean values found was 0.2±0.07 for MPS II, 0.02±0.07 for MPS I and 0.07±0.01 for MPS VI. For cell death (pyknosis, karyorrhexis and karyolysis), the MPS VI had the higher score (34.2±13.4), followed by MPS II (23.7±11.3), and MPS I (20.6±8.5). Conclusions:Our results suggest that genotoxicity and cytotoxicity were more evident in mucosa bucal and peripheral blood from MPS patients than control subjects. Concerning the three types of MPS, the oral findings were evident, mainly in MPS VI patients which, in our sample, begun enzyme replacement therapy more lately than the others MPS.